SB Emerges From Merger Talks Up 35% As Rx Rally Completes Fourth Year
Executive Summary
SmithKline Beecham's very visible merger discussions in 1998 may have created a "virtual" merger strategy that benefited the whole pharmaceutical sector in another banner year for drug stocks on Wall Street.